The FDA has accepted a biologics license application seeking the approval of crovalimab for use in patients with paroxysmal nocturnal hemoglobinuria.
Related Keywords
Levi Garraway , Genentech , Global Product Development , Key Objectives , Eligibility Criteria , Bend Points , Hematologic Oncology , News ,
comparemela.com © 2020. All Rights Reserved.